Characteristics and long-term outcome of patients with autoimmune hepatitis related to the initial treatment response

Scandinavian Journal of Gastroenterology

Volumn 45, Issue 4, 2010, Pages 457-467

  Werner, Mårten ^a   Wallerstedt, Sven ^b   Lindgren, Stefan ^c   Almer, Sven ^d   Björnsson, Einar ^b   Bergquist, Annika ^e   Prytz, Hanne ^c   Sandberg Gertzén, Hanna ^f   Hultcrantz, Rolf ^e   Sangfelt, Per ^g   Weiland, Ola ^e   Ohlsson, Bodil ^c   Danielsson, Äke ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^g UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Autoimmune hepatitis; Azathioprine; Cirrhosis; Follow up; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; AZATHIOPRINE; BILIRUBIN; GLUCOCORTICOID; IMMUNOGLOBULIN; MERCAPTOPURINE; PREDNISOLONE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; BILIRUBIN BLOOD LEVEL; BLOOD CHEMISTRY; BONE MARROW DEPRESSION; BRAIN DISEASE; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CHILD; CLINICAL FEATURE; CORONARY ARTERY DISEASE; CUSHINGOID SYNDROME; DECOMPENSATED LIVER CIRRHOSIS; DEMENTIA; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; ESOPHAGUS VARICES; FATIGUE; FEMALE; FEVER; FRACTURE; GASTROINTESTINAL HEMORRHAGE; HAIR LOSS; HEADACHE; HEPATITIS; HISTOPATHOLOGY; HUMAN; HYPERTENSION; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION; INTERNATIONAL NORMALIZED RATIO; JAUNDICE; LEUKOPENIA; LIVER CANCER; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MYALGIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPENIA; OVERALL SURVIVAL; PANCREATITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; RASH; RISK FACTOR; SCHOOL CHILD; SHOCK; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; VARICOSIS; VASCULAR DISEASE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CAUSE OF DEATH; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK FACTORS; SURVIVAL RATE; SWEDEN; TREATMENT OUTCOME;

EID: 77949884313     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365520903555861     Document Type: Article

References (33)

1. Waldenström J. Leber, Blutprotein und Nahrungseisse. Dtsch Gesellsh Verd Stoffw 1950;5:113-119
2. McFarlane IG. The relationship between autoimmune markers and different clinical syndromes in autoimmune hepatitis. Gut 1998;42:599-602
3. Werner M, Prytz H, Ohlsson B, Almer S, Bjornsson E, Bergquist A, et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol 2008;43:1232-1240
4. Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006; 354:54-66
5. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995;333:958-963
6. Al-Chalabi T, Portmann BC, Bernal W, McFarlane IG, Heneghan MA. Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival. Aliment Pharmacol Ther 2008;28:209-220
7. Soloway RD, Summerskill WH, Baggenstoss AH, Geall MG, Gitnick GL, Elveback IR, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972;63:820-833
8. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973;1:735-737
9. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971;40:159-185
10. Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996;110:848-857
11. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002;36:479-497
12. Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005; 42:53-62
13. Manns MP, Vogel A. Autoimmune hepatitis, from mechanisms to therapy. Hepatology 2006;43:S132-44
14. Sherlock S, Dooley J. Diseases of the liver and biliary system. 11th ed., Blackwell, 2002
15. Montano-Loza AJ, Carpenter HA, Czaja AJ. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int 2007;27:507-515
16. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-938
17. Werner M, Bjornsson E, Prytz H, Lindgren S, Almer S, Broome U, et al. Autoimmune hepatitis among fertile women: strategies during pregnancy and breastfeeding? Scand J Gastroenterol 2007;42:986-991
18. Werner M, Almer S, Prytz H, Lindgren S, Wallerstedt S, Bjornsson E, et al. Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients. J Hepatol 2009;50:388-393
19. Swedish National Board of Health and Welfare. Cancer incidence in Sweden 2006. Available from: www. socialstyrelsen.se
20. Swedish National Board of Health and Welfare. Quality of death cause register. Available from: www.socialstyrelsen.se
21. Swedish National Board of Health and Welfare. Causes of death 2006. Available from: www.socialstyrelsen.se
22. European transplant register 2007. Available from: www.elt.org
23. Al-Chalabi T, Underhill JA, Portmann BC, McFarlane IG, Heneghan MA. Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis. J Hepatol 2008;48:140-147
24. Manns MP, Strassburg CP. Autoimmune hepatitis: clinical challenges. Gastroenterology 2001;120:1502-1517
25. Czaja AJ, Davis GL, Ludwig J, Taswell HF. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 1984;4:622-627
26. Poulsen LO, Thulstrup AM, Mellemkjaer L, Vilstrup H, Sorensen HT. Mortality and causes of death in patients with "lupoid hepatitis". A long-term follow-up study in Denmark. Dan Med Bull 2002;49:263-265
27. Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004; 99:1510-1516
28. Gisbert JP, Gonzalez-Lama Y, Mate J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol 2007;102:1518-1527
29. de Jong DJ, Derijks LJ, Naber AH, Hooymans PM, Mulder CJ. Safety of thiopurines in the treatment of inflammatory bowel disease. Scand J Gastroenterol Suppl 2003;239:69-72
30. Al-Chalabi T, Boccato S, Portmann BC, McFarlane IG, Heneghan MA. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol 2006;45:575-583
31. Sanderson J, Ansari A, Marinaki T, Duley J. Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy? Ann Clin Biochem 2004;41: 294-302
32. Heneghan MA, Allan ML, Bornstein JD, Muir AJ, Tendler DA. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. J Hepatol 2006;45:584-591
33. Hindorf U, Jahed K, Bergquist A, Verbaan H, Prytz H, Wallerstedt S, et al. Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis. J Hepatol 2010, in press